Lundbeck Convinces NICE To Back Brintellix In MDD
This article was originally published in Scrip
Executive Summary
NICE has decided to recommend H. Lundbeck AS' Brintellix (vortioxetine) for funding on the National Health Service in England and Wales after requesting and receiving more information from the Danish company on the novel antidepressant.